Research and development of engineered antibody-based products.
GLYCART biotechnology AG was active in the research and development of engineered antibody-based products with higher efficacy for the treatment of unmet clinical needs such as cancer.
GLYCART biotechnology AG was acquired by Roche in 2005 for CHF 230 million.
Human Health
Industry
Biotech
Status
Realised
Location
Switzerland